Pirfenidone is InterMune's investigational drug candidate for the treatment of patients with idiopathicpulmonaryfibrosis to reduce decline in lung function.
Hilgartner, now 67, was diagnosed with idiopathicpulmonaryfibrosis (IPF), one of the more lethal forms of severe fibrotic conditions that afflict more than 10 million Americans.